Table 1. Phase III trials in high risk prostate cancer (modified from K. Fizazi).
| Study name | Local tumor treatment | Design of the study | Primary end point | Status |
|---|---|---|---|---|
| GETUG 12 | XRT | Neoadj DE + ADT (3 years) vs. local therapy + ADT (3 years) | PFS | Accrual completed |
| CALGB 90203 | RP | Neoadj D (6 cycles) + ADT (18-24 weeks) prior to RP vs. RP alone | PFS | Ongoing |
| RTOG 0521 | XRT | Adj D+ ADT (2 years) vs. ADT (2 years) | OS | Accrual completed |
| TAX 3501 | RP | Adj D (6 cycles) + ADT vs. ADT | PFS | Early accrual termination |
| VA # 553 CAP | RP | Adj D (6 cycles) vs. observation | PFS | Ongoing |
| AdPro | RP | Adj D (6 cycles) vs. surveillance | TTF | Accrual completed |
| AdRad | XRT | Adj D (6cycles) + ADT vs. ADT | PSA progression rate | Ongoing |
| DANA FARBER | XRT | Neoadj D (6 cycles) + ADT vs. ADT (6 cycles) | OS | Ongoing |
XRT, external radiation therapy; ADT, androgen deprivation therapy; PFS, progression free survival; RP, radical prostatectomy; D, docetaxel; DE, docetaxel plus estramustine; TTF, time to treatment failure.